A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system

Published:2021-12-31 Issue: Volume: Page:1-10
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Shu Yamin¹,Ding Yufeng¹,Dai Bing²,Zhang Qilin³

Affiliation:

1. Department of Pharmacy, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China

2. West China Pharmaceutical College, Sichuan University, Chengdu, China

3. Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Funder

National Natural Science Foundation of China

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2022.2016696

Reference38 articles.

1. The efficacy of axitinib as a first‐line treatment for metastatic renal cell carcinoma

2. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

3. Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year

4. First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data

5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A real-world disproportionality analysis of Baloxavir Marboxil: post-marketing pharmacovigilance data;Expert Opinion on Drug Safety;2024-09-05

2. Ocular adverse events associated with antibody-drug conjugates in oncology: a pharmacovigilance study based on FDA adverse event reporting system (FAERS);Frontiers in Pharmacology;2024-08-20

3. Post-marketing safety concerns with relugolix: a disproportionality analysis of the FDA adverse event reporting system;Investigational New Drugs;2024-08-12

4. Cytokine release syndrome associated with immune checkpoint inhibitors: a pharmacovigilance study based on spontaneous reports in FAERS;Expert Opinion on Drug Safety;2024-07-29

5. Adverse events in different administration routes of semaglutide: a pharmacovigilance study based on the FDA adverse event reporting system;Frontiers in Pharmacology;2024-06-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3